Skip to main content

Advertisement

SpringerLink
Log in

IL-2 mediates NK cell proliferation but not hyperactivity

  • Original Article
  • Published:
Immunologic Research Aims and scope Submit manuscript

Abstract

Natural killer cells play a major role in innate immunity against tumor and virus-infected cells. NK cells express activating and inhibitory receptors to regulate their function. It has been established that modulation in the NK cell receptor profile results in altered function of NK cell against target cells. Here, we study the effect of IL-2 stimulation on NK cell inhibitory receptors Ly49A, Ly49C, and activating receptor Ly49D in C57BL/6 mice. It was observed that there was significant increase in expression of Ly49A but no change in expression of Ly49C and Ly49D on IL-2 stimulation. We further noticed that although IL-2 stimulation increased the NK cell population and expression of activation marker NK1.1 but IL-2 stimulation does not cause hyper-responsiveness in NK cells, as there was no increase in MIP-1α and IFN-γ production in IL-2 stimulated NK cells as compared to unstimulated controls. These findings provide a framework to understand the effect of IL-2 stimulation on cognate and non-cognate receptor ligand interactions and suggest stratagies for immunotherapies in conjunction with IL-2 combinatorial therapies.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

References

  1. Duck Cho MD, Dario Campana MD. Expansion and activation of natural killer cells for cancer immunotherapy. Korean J Lab Med. 2009;29(2):89–96.

    Article  PubMed  PubMed Central  Google Scholar 

  2. Atkins MB, Kunkel L, Sznol M, Rosenberg SA. High-dose recombinant interleukin-2 therapy in patients with metastatic melanoma: long-term survival update. Cancer J Sci Am. 2000:6(1):S11–4.

  3. Boyman O, Sprent J. The role of interleukin-2 during homeostasis and activation of the immune system. Nat Rev Immunol. 2012;12(3):180–90. https://doi.org/10.1038/nri3156.

    Article  CAS  PubMed  Google Scholar 

  4. Sim GC, Radvanyi L. The IL-2 cytokine family in cancer immunotherapy. Cytokine Growth Factor Rev. 2014;25(4):377–90. https://doi.org/10.1016/j.cytogfr.2014.07.018.

    Article  CAS  PubMed  Google Scholar 

  5. Ohtani H, Mori-Shiraishi K, Nakajima M, Ueki H. Defining lymphocyte-predominant breast cancer by the proportion of lymphocyte-rich stroma and its significance in routine histopathological diagnosis. Pathol Int. 2015;65(12):644–51. https://doi.org/10.1111/pin.12355.

    Article  PubMed  PubMed Central  Google Scholar 

  6. Dushyanthen S, Beavis PA, Savas P, Teo ZL, Zhou C, Mansour M, et al. Relevance of tumor-infiltrating lymphocytes in breast cancer. BMC Med. 2015;13(1):202. https://doi.org/10.1186/s12916-015-0431-3.

    Article  PubMed  PubMed Central  Google Scholar 

  7. Rosenberg SA, Yang JC, Sherry RM, Kammula US, Hughes MS, Phan GQ, et al. Durable complete responses in heavily pretreated patients with metastaticmelanoma using T-cell transfer immunotherapy. Clin Cancer Res. 2011;17(13):4550–7. https://doi.org/10.1158/1078-0432.CCR-11-0116.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Hwang WT, Adams SF, Tahirovic E, Hagemann IS, Coukos G. Prognostic significance of tumor-infiltrating T cells in ovarian cancer: a meta-analysis. Gynecol Oncol. 2012;124(2):192–8. https://doi.org/10.1016/j.ygyno.2011.09.039.

    Article  PubMed  Google Scholar 

  9. Stevanovic S, Draper LM, Langhan MM, Campbell TE, Kwong ML, Wunderlich JR, et al. Complete regression of metastatic cervical cancer after treatment with human papillomavirus-targeted tumor-infiltrating T cells. J Clin Oncol 2015:33(14):1543–50.

  10. Schleypen JS, Baur N, Kammerer R, Nelson PJ, Rohrmann K, Grone EF, et al. CytotoxicMarkers and frequency predict functional capacity of natural killer cells infiltrating renal cell carcinoma. Clin Cancer Res. 2006;12(3):718–25. https://doi.org/10.1158/1078-0432.CCR-05-0857.

    Article  CAS  PubMed  Google Scholar 

  11. Basse PH, Goldfarb RH, Herberman RB, Hokland ME. Accumulation of adoptively transferred ANK cells in murine metastases: kinetics and role of interleukin-2. In Vivo Athens Greece 1994;8(1):17–24.

  12. Yang Q, Hokland ME, Bryant JL, Zhang Y, Nannmark U, Watkins SC, et al. Tumor-localization by adoptively transferred, interleukin-2-activated NK cells leads to destruction of well-established lung metastases. Int J Cancer. 2003;105(4):512–9. https://doi.org/10.1002/ijc.11119.

    Article  CAS  PubMed  Google Scholar 

  13. Sarkar S, Germeraad WT, Rouschop KM, Steeghs EM, Van Gelder M, Bos GM, et al. Hypoxia induced impairment of NK cell cytotoxicity against multiple myeloma can be overcome by IL-2 activation of the NK cells. PLoS One. 2013;8(5):e64835. https://doi.org/10.1371/journal.pone.0064835.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Moon EK, Wang LC, Dolfi DV, Wilson CB, Ranganathan R, Sun J, et al. Multifactorial T-cell hypofunction that is reversible can limit the efficacy of chimeric antigen receptor-transduced human T cells in solid tumors. Clin Cancer Res. 2014;20(16):4262–73. https://doi.org/10.1158/1078-0432.CCR-13-2627.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Navarro AG, Björklund AT, Chekenya M. Therapeutic potential and challenges of natural killer cells in treatment of solid tumors. Front Immunol. 2015;6:202.

    Google Scholar 

  16. Kunert A, Straetemans T, Govers C, Lamers C, Mathijssen R, Sleijfer S, et al. TCR-engineered T cells meet new challenges to treat solid tumors: choice of antigen, T cell fitness, and sensitization of tumor milieu. Front Immunol. 2013;4:363.

    Article  PubMed  PubMed Central  Google Scholar 

  17. Tahtinen S, Kaikkonen S, Merisalo-Soikkeli M, Grönberg-Vaha-Koskela S, Kanerva A, Parviainen S, et al. Favorable alteration of tumor microenvironment by immunomodulatory cytokines for efficient T-cell therapy in solid tumors. PLoS One. 2015;10(6):e0131242. https://doi.org/10.1371/journal.pone.0131242.

    Article  PubMed  PubMed Central  Google Scholar 

  18. Schleypen JS, Von Geldern M, Weiss EH, Kotzias N, Rohrmann K, Schendel DJ, et al. Renal cell carcinoma-infiltrating natural killer cells express differential repertoires of activating and inhibitory receptors and are inhibited by specific HLA class I allotypes. Int J Cancer. 2003;106(6):905–12. https://doi.org/10.1002/ijc.11321.

    Article  CAS  PubMed  Google Scholar 

  19. Bottino C, Castriconi R, Pende D, Rivera P, Nanni M, Carnemolla B, et al. Identification of PVR (CD155) and Nectin-2 (CD112) as cell surface ligands for the human DNAM-1 (CD226) activating molecule. J Exp Med. 2003;198(4):557–67. https://doi.org/10.1084/jem.20030788.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Poggi A, Zocchi MRNK. Cell autoreactivity and autoimmune diseases. Front Immunol. 2014;5:27.

    PubMed  PubMed Central  Google Scholar 

  21. Schleinitz N, Vely F, Harle J-R, Vivier E. Natural killer cells in human autoimmune diseases. Immunology. 2010;131(4):451–8. https://doi.org/10.1111/j.1365-2567.2010.03360.x.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Fogel LA, Yokoyama WM, French AR. Natural killer cells in human autoimmune disorders. Arthritis Res Ther. 2013;15(4):216. https://doi.org/10.1186/ar4232.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Akesson C, Uvebrant K, Oderup C, Lynch K, Harris RA, Lernmark A, et al. Altered natural killer (NK) cell frequency and phenotype in latent autoimmune diabetes in adults (LADA) prior to insulin deficiency. Clin Exp Immunol. 2010;161(1):48–56. https://doi.org/10.1111/j.1365-2249.2010.04114.x.

    CAS  PubMed  PubMed Central  Google Scholar 

  24. Zhang Y, Wang H, Lou X, Qu X, Gao L, Liu X, et al. Decreased percentage of NKG2D+NK cells in patients with incident onset of type 1 diabetes. Clin Exp Pharmacol Physiol. 2017;44(2):180–90. https://doi.org/10.1111/1440-1681.12699.

    Article  CAS  PubMed  Google Scholar 

  25. Nabekura T, Lanier LL. Activating receptors for self-MHC class I enhance effector functions and memory differentiation of NK cells during mouse cytomegalovirus infection. Immunity. 2016;45(1):74–82. https://doi.org/10.1016/j.immuni.2016.06.024.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Reichlin A, Yokoyama WM. Natural killer cell proliferation induced by anti-NK1.1 and IL-2. Immunol Cell Biol. 1998;76(2):143–52. https://doi.org/10.1046/j.1440-1711.1998.00726.x.

    Article  CAS  PubMed  Google Scholar 

  27. Kritikou JS, Dahlberg CI, Baptista MA, Wagner AK, Banerjee PP, Gwalani LA, et al. IL-2 in the tumor microenvironment is necessary for Wiskott-Aldrich syndrome protein deficient NK cells to respond to tumors in vivo. Sci Rep. 2016;6:30636.

  28. Pauza M, Smith KM, Neal H, Reilly C, Lanier LL, Lo D. Transgenic expression of Ly-49A in thymocytes alters repertoire selection. J Immunol. 2000;164(2):884–92. https://doi.org/10.4049/jimmunol.164.2.884.

    Article  CAS  PubMed  Google Scholar 

  29. Hanke T, Raulet DH. Cumulative inhibition of NK cells and T cells resulting from engagement of multiple inhibitory Ly49 receptors. J Immunol. 2001;166(5):3002–7. https://doi.org/10.4049/jimmunol.166.5.3002.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

We thank Dr. A.N Bhatt, Institute of Nuclear Medicine and Allied Sciences for providing us the mice model and instrument facility. Authors are thankful to DST-SERB for providing financial support for the present study. Authors would like to acknowledge DTU for providing research fellowship to Richa Sharma and also providing infrastructure facilities.

All experiments involving animals were performed in Institute of Nuclear Medicine and Allied Sciences. All procedures performed in studies involving animals were in accordance with the ethical standards of the institution or practice at which the studies were conducted.

Author information

Authors and Affiliations

  1. Department of Biotechnology, Delhi Technological University, Main Bawana Road, Shahbad Daulatpur, New Delhi, Delhi, 110042, India

    Richa Sharma & Asmita Das

Authors
  1. Richa Sharma
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Asmita Das
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Asmita Das.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Sharma, R., Das, A. IL-2 mediates NK cell proliferation but not hyperactivity. Immunol Res 66, 151–157 (2018). https://doi.org/10.1007/s12026-017-8982-3

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12026-017-8982-3

Keywords

Search

Navigation